Tokyo Tape
Sign in
← PeptiDream

Half-year report · Q2

4587.TEDINET S100WHGM
Period2025-01-01 → 2025-06-30
Filed2025-08-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥8.5bn2025-01-01 → 2025-06-30Cons.Revenue IFRS
Revenue¥46.7bn2024-01-01 → 2024-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥36.1bn2024-01-01 → 2024-06-30Cons.Revenue IFRS
Operating income−¥2.6bn2025-01-01 → 2025-06-30Cons.Operating profit loss IFRS
Operating income¥24.6bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Profit before tax−¥2.9bn2025-01-01 → 2025-06-30Cons.Profit loss before tax IFRS
Profit before tax¥20.9bn2024-01-01 → 2024-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥24.7bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Net income (owners)−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.0bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss IFRS
Net income¥15.0bn2024-01-01 → 2024-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Total assets¥78.5bnat 2025-06-30Cons.Assets IFRS
Total assets¥92.8bnat 2024-12-31Cons.Assets IFRS
Total assets¥95.9bnat 2024-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥24.9bnat 2025-06-30Cons.Liabilities IFRS
Total liabilities¥36.0bnat 2024-12-31Cons.Liabilities IFRS
Net assets / equity¥53.7bnat 2025-06-30Cons.Equity IFRS
Net assets / equity¥56.8bnat 2024-12-31Cons.Equity IFRS
Net assets / equity¥58.8bnat 2024-06-30Cons.Equity IFRS
Net assets / equity¥40.3bnat 2023-12-31vCons.Equity IFRS
Equity (owners)¥53.7bnat 2025-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥56.8bnat 2024-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥58.8bnat 2024-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥33.3bnat 2025-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥48.1bnat 2024-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥25.5bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.5bnat 2023-12-31vCons.Cash and cash equivalents IFRS
Operating cash flow−¥11.0bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥23.8bn2024-01-01 → 2024-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥2.7bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥1.3bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥8.4bn2024-01-01 → 2024-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow¥10.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.5bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥3.0bn2024-01-01 → 2024-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-16.42025-01-01 → 2025-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥115.852024-01-01 → 2024-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥138.32024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-16.42025-01-01 → 2025-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥115.682024-01-01 → 2024-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥138.112024-01-01 → 2024-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio68.3%at 2025-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.2%at 2024-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.3%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-06-30−¥453m
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-06-30−¥453m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥761m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥761m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥3.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥8.2bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥7.8bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥453m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2025-01-01 → 2025-06-30¥436m
—segment totalrevenue2025-01-01 → 2025-06-30¥9.0bn
—segment totalrevenue external2025-01-01 → 2025-06-30¥8.5bn
—segment totalrevenue intersegment2025-01-01 → 2025-06-30¥453m
—segment totalsegment profit2025-01-01 → 2025-06-30−¥2.6bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥178m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥178m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2024-01-01 → 2024-06-30¥24.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥7.8bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥7.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥178m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥47m
—segment totalrevenue2024-01-01 → 2024-06-30¥36.3bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥36.1bn
—segment totalrevenue intersegment2024-01-01 → 2024-06-30¥178m
—segment totalsegment profit2024-01-01 → 2024-06-30¥24.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 582
ItemContextValueUnit
Inventories ca IFRSPrior1YearInstant2671658000JPY
Inventories ca IFRSCurrentQuarterInstant3066743000JPY
Income taxes receivable ca IFRSPrior1YearInstant－JPY
Income taxes receivable ca IFRSCurrentQuarterInstant808102000JPY
Other current assets ca IFRSPrior1YearInstant1130906000JPY
Other current assets ca IFRSCurrentQuarterInstant894420000JPY
Current assets IFRSPrior1YearInstant57209634000JPY
Current assets IFRSCurrentQuarterInstant42599528000JPY
Property plant and equipment IFRSPrior1YearInstant17526094000JPY
Property plant and equipment IFRSCurrentQuarterInstant17673132000JPY
Goodwill IFRSPrior1YearInstant8370677000JPY
Goodwill IFRSCurrentQuarterInstant8370677000JPY
Intangible assets IFRSPrior1YearInstant2142969000JPY
Intangible assets IFRSCurrentQuarterInstant2066316000JPY
Investments accounted for using equity method IFRSPrior1YearInstant64796000JPY
Investments accounted for using equity method IFRSCurrentQuarterInstant32890000JPY
Other financial assets nca IFRSPrior1YearInstant2558989000JPY
Other financial assets nca IFRSCurrentQuarterInstant2851011000JPY
Deferred tax assets IFRSPrior1YearInstant4732551000JPY
Deferred tax assets IFRSCurrentQuarterInstant4733969000JPY
Retirement benefit asset nca IFRSPrior1YearInstant73115000JPY
Retirement benefit asset nca IFRSCurrentQuarterInstant72881000JPY
Other non current assets nca IFRSPrior1YearInstant90996000JPY
Other non current assets nca IFRSCurrentQuarterInstant137215000JPY
Non current assets IFRSPrior1YearInstant35560191000JPY
Non current assets IFRSCurrentQuarterInstant35938094000JPY
Assets IFRSPrior1YearInstant92769826000JPY
Assets IFRSCurrentQuarterInstant78537623000JPY
Trade and other payables cl IFRSPrior1YearInstant5332036000JPY
Trade and other payables cl IFRSCurrentQuarterInstant3213446000JPY
Borrowings cl IFRSPrior1YearInstant2592935000JPY
Borrowings cl IFRSCurrentQuarterInstant2596176000JPY
Other financial liabilities cl IFRSPrior1YearInstant320940000JPY
Other financial liabilities cl IFRSCurrentQuarterInstant270485000JPY
Income taxes payable cl IFRSPrior1YearInstant8039345000JPY
Income taxes payable cl IFRSCurrentQuarterInstant46818000JPY
Provisions cl IFRSPrior1YearInstant26521000JPY
Provisions cl IFRSCurrentQuarterInstant4641000JPY
Contract liabilities cl IFRSPrior1YearInstant1105984000JPY
Contract liabilities cl IFRSCurrentQuarterInstant1185077000JPY
Other current liabilities cl IFRSPrior1YearInstant989009000JPY
Other current liabilities cl IFRSCurrentQuarterInstant859238000JPY
Total current liabilities IFRSPrior1YearInstant18406773000JPY
Total current liabilities IFRSCurrentQuarterInstant8175883000JPY
Borrowings ncl IFRSPrior1YearInstant17041512000JPY
Borrowings ncl IFRSCurrentQuarterInstant15742425000JPY
Other financial liabilities ncl IFRSPrior1YearInstant398758000JPY
Other financial liabilities ncl IFRSCurrentQuarterInstant372574000JPY
Retirement benefit liability ncl IFRSPrior1YearInstant78328000JPY
Retirement benefit liability ncl IFRSCurrentQuarterInstant56591000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identityconsolidated 2025-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsconsolidated 2025-06-30pass